Cardiac molecular imaging stands at the forefront of cardiovascular research, employing state-of-the-art imaging methodologies to unravel the intricate molecular dynamics within the heart. This innovative field enables a comprehensive exploration of the cellular and molecular intricacies that dictate cardiac function and health. Through the application of specialized imaging agents, scientists can pinpoint and study specific molecular indicators linked to various cardiovascular conditions. The precision offered by cardiac molecular imaging holds the potential for transformative advancements in early disease detection, accurate diagnosis, and the development of personalized therapeutic approaches. This evolving discipline is poised to redefine our understanding of cardiovascular health by shedding light on the nuanced molecular pathways, opening avenues for more targeted interventions and improved patient care.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States